HLX15-SC

HLX15-SC · Shanghai Henlius Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HLX15-SC, covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1]

See pricing